<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049447</url>
  </required_header>
  <id_info>
    <org_study_id>200S14PF</org_study_id>
    <nct_id>NCT05049447</nct_id>
  </id_info>
  <brief_title>Pharmacological Effects of Pascoflair® on Brain Activity in Patients Suffering From Test Anxiety</brief_title>
  <official_title>Proof of Effectiveness of Pascoflair Using Qantitative Measurement of Electric Brain Activity During Examination Stress in 40 Subjects Suffering From Test Anxiety. A Double-blind, Randomized, Placebo-controlled, 2-armed, Phase IV Study in Parallel Design.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pascoe Pharmazeutische Praeparate GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NeuroCode AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pascoe Pharmazeutische Praeparate GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of effectiveness of Pascoflair using qantitative measurement of electric brain activity&#xD;
      during examination stress in 40 subjects suffering from test anxiety. A double-blind,&#xD;
      randomized, placebo-controlled, 2-armed, Phase IV study in parallel design.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anxiolytic effects of PASCOFLAIR® shall be tested in subjects suffering from test anxiety&#xD;
      after single intake by aid of a newly developed, validated method consisting of a combination&#xD;
      of eye tracking (following glances) with neurocode tracking (quantitative EEG with a time&#xD;
      resolution of 364 ms).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of verum and placebo Beta 1 power</measure>
    <time_frame>day A (treatment day) - 1 day</time_frame>
    <description>Comparison of verum and placebo efficacy is performed on electric power in 17 different brain regions within six frequency ranges defined as target parameters in the presence of different stress inducing cognitive tests or exciting video scenes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerability in a 4- Point scale</measure>
    <time_frame>Final examination (day AB) -1 day</time_frame>
    <description>Tolerability in a 4- Point scale (very good, good, moderately, poor)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.</measure>
    <time_frame>Final examination - 1 day</time_frame>
    <description>Correlation between questionnaire items and spectral EEG power with regard to different frequency ranges.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Stress</condition>
  <condition>Brain Activity</condition>
  <condition>Passiflora Incarnata</condition>
  <condition>Test Anxiety</condition>
  <arm_group>
    <arm_group_label>Verum arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention: Drug: Verum (Pascoflair)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Intervention: Drug: Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pascoflair</intervention_name>
    <description>1 x 2 tablets (single-dose)</description>
    <arm_group_label>Verum arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 x 2 tablets (single-dose)</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy male and female subjects.&#xD;
&#xD;
          -  Age between 18 and 40 years (both included).&#xD;
&#xD;
          -  Anxiety questionnaire PAF (pre-selection of subjects) - values above T&gt; 60 are&#xD;
             regarded as conclusive.&#xD;
&#xD;
          -  Inconclusive case history and diagnosis.&#xD;
&#xD;
          -  Subject must be capable of giving informed consent.&#xD;
&#xD;
          -  Acceptance of written consent to participate in the study after education in written&#xD;
             and oral form (informed consent).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute or chronic disease with an impact on the study, which becomes obvious by case&#xD;
             history or clinical examination.&#xD;
&#xD;
          -  Clinically relevant pathological findings from clinical and laboratory findings.&#xD;
&#xD;
          -  Presence of clinically relevant pathological EEG features or artifact-free portion of&#xD;
             the screening EEG &lt;30%.&#xD;
&#xD;
          -  Clinically relevant allergic symptoms.&#xD;
&#xD;
          -  Detection of alcohol at the time of initial examination (day SC) or on study day A&#xD;
             (positive alcohol test) or by case history.&#xD;
&#xD;
          -  Detection of drugs (positive drug test) at the time of initial examination (day SC).&#xD;
&#xD;
          -  Consumption of clinically relevant medication during last fourteen days before and&#xD;
             during the active study period based on the notification of the subject or his case&#xD;
             history.&#xD;
&#xD;
          -  Consumption of medication with primarily central action (i.e. psychotropic drugs or&#xD;
             centrally acting antihypertensives).&#xD;
&#xD;
          -  Known intolerance / hypersensitivity (allergy) to plant derived extracts (Passion&#xD;
             flower dry extract) or any of the ingredients of the investigational product&#xD;
             (anamnestic).&#xD;
&#xD;
          -  Presence of a rare, genetic disease such as fructose intolerance, glucosegalactose&#xD;
             malabsorption or sucrase-isomaltase deficiency (anamnestic).&#xD;
&#xD;
          -  BMI (Body Mass Index) &lt;18 or&gt; 32.&#xD;
&#xD;
          -  Consumption of unusual quantities or misuse of coffee (more than 4 cups a day), tea&#xD;
             (more than 4 cups a day) or tobacco (more than 20 cigarettes per day).&#xD;
&#xD;
          -  Smoking on day of A.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 21, 2015</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anxiety Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

